The first Alzheimer's drug will be available in the Czech Republic. The Ministry is selecting suitable centers

Czech patients with mild Alzheimer's disease could have access to a breakthrough treatment that will slow the progression of the disease early next year. The first drug of its kind in Europe, lecanemab, was approved by the European Commission last week, and the Japanese company Eisai, which is behind it, wants to offer it to patients in the Czech Republic.